Obermatt
See Similar Stocks →

IQVIA

NYQ:IQV · US46266C1053
Life Sciences Tools & ServicesX-Large

360

49
EV / EBIT67
Price / Owner Earnings52
Owner Earnings Yield77
Dividend Yield1
Price/Sales84
EV / Gross Profit63
Price/Book38
Return on Capital69
Cash Return on Capital71
Return on Equity90
EBIT Margin53
Gross Profitability53
Cash Conversion57
Accruals27
Owner Earnings Margin61
Sales growth36
Profit Growth98
Long-Term EPS Growth60
Owner Earnings Growth62
Reinvestment39
Price momentum59
Debt load14
Refinancing14
Debt Payback22
Liquidity70
Analyst ratings51
Opinion Changes50
Price Target Upside67
Market mood85
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

IQVIA clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
TypePublic Company
ExchangeNYSE
Employees56,081
Websiteir.iqvia.com
ISINUS46266C1053
Last UpdateApr 2, 2026
Indices
S&P 500 (USA)D.J. US Health Care
Themes
Online Analysis and ReferenceGeneticsData IntegrationDaaSHealth DiagnosticsPredictive AnalyticsArtificial IntelligenceAnalyticsHealth CareLife Science

Description

IQVIA Holdings Inc. (IQVIA) provides clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries globally. IQVIA’s portfolio of solutions is powered by IQVIA Connected Intelligence to de…

Analysis

Middle-of-the-road

IQVIA Holdings Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is fair. You pay 20.6× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 7% yearly growth; analysts expect 11%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is fragile. The company scores 12/20 on our value-creation score: creating some value.

What to watch: The financial cushion is thinner than comfortable. A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
69
2023202420252026

All-time high

69

Jun 2026

All-time low

10

Jan 2024

Average rank

39

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
84
60
56
67
Price/Earnings
31
84
82
62
Price/Book
38
24
15
18
Dividend Yield
1
1
1
1
Value (overall)
48
55
43
41

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare IQVIA with its peers
Zevra Therapeutics
NSQ:ZVRA
92
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Trevi Therapeutics
NMQ:TRVI
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Innoviva
NSQ:INVA
95
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Bio-Techne
NSQ:TECH
74
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Repligen
NSQ:RGEN
66
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
NervGen Pharma
CVE:NGEN
44
CountryCanada
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →